# A Phase I/II Study of HE3235 in Patients With Prostate Cancer

> **NCT00716794** · PHASE1,PHASE2 · COMPLETED · sponsor: **Harbor Therapeutics** · enrollment: 64 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** HE3235

## Key facts

- **NCT ID:** NCT00716794
- **Lead sponsor:** Harbor Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2011-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716794, "A Phase I/II Study of HE3235 in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00716794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*